Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 5.
doi: 10.1002/oby.24362. Online ahead of print.

Long-Term Medication-Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study

Han Yu  1 , Jessica G Young  1   2 , Joshua Petimar  1   2 , Sheryl L Rifas-Shiman  1 , Matthew F Daley  3 , William J Heerman  4 , David M Janicke  5 , W Schuyler Jones  6   7 , Takuya Kawahara  1   8 , Kristina H Lewis  9 , Pi-I D Lin  1 , Sengwee Toh  1 , Daniel S Weisholtz  10 , Jason P Block  1
Affiliations

Long-Term Medication-Induced Weight Change Across Common Antiseizure Medications: A Target Trial Emulation Study

Han Yu et al. Obesity (Silver Spring). .

Abstract

Objective: To estimate long-term weight change after initiation and adherence to commonly used antiseizure medications (ASMs) and examine differences in weight change across ASMs compared to topiramate.

Methods: We included 52,309 adult patients who initiated ASMs, applied a target trial emulation approach to control time-varying confounding and selection bias, and examined the long-term comparative effects on weight change after initiating and adhering to different ASMs at 6 and 12 months post initiation.

Results: The most commonly initiated ASM was topiramate (41.2%). In comparison to topiramate, we estimated higher 6-month weight change under initiation and adherence to levetiracetam 0.94 kg (95% CI 0.20, 1.64), lamotrigine 1.44 kg (0.74, 1.99), valproate 2.42 kg (1.71, 2.88), carbamazepine 1.32 kg (0.46, 2.16), and oxcarbazepine 1.74 kg (0.85, 2.71), with similar results at 12 months and in sensitivity and subgroup analyses. These results were driven mostly by weight loss with use of topiramate rather than weight gain with use of other ASMs. Results were similar though attenuated when accounting for medication initiation only.

Conclusions: Topiramate was associated with weight loss at 6 and 12 months under either initiation and subsequent adherence or initiation-only effects; other medications were associated with higher weight change. These results provided important information to help with decision-making regarding ASM initiation.

Keywords: antiseizure medication; obesity; target trial emulation; weight change.

PubMed Disclaimer

References

    1. M. Musicco, E. Beghi, A. Solari, and F. Viani, “Treatment of First Tonic‐Clonic Seizure Does Not Improve the Prognosis of Epilepsy First Seizure Trial Group (FIRST Group),” Neurology 49, no. 4 (1997): 991–998, https://doi.org/10.1212/wnl.49.4.991.
    1. A. M. Kanner and M. M. Bicchi, “Antiseizure Medications for Adults With Epilepsy: A Review,” JAMA 327, no. 13 (2022): 1269–1281, https://doi.org/10.1001/jama.2022.3880.
    1. E. Brodtkorb, C. Samsonsen, J. K. Sund, G. Bråthen, G. Helde, and A. Reimers, “Treatment Non‐Adherence in Pseudo‐Refractory Epilepsy,” Epilepsy Research 122 (2016): 1–6, https://doi.org/10.1016/j.eplepsyres.2016.02.001.
    1. R. Manjunath, K. L. Davis, S. D. Candrilli, and A. B. Ettinger, “Association of Antiepileptic Drug Nonadherence With Risk of Seizures in Adults With Epilepsy,” Epilepsy & Behavior 14, no. 2 (2009): 372–378, https://doi.org/10.1016/j.yebeh.2008.12.006.
    1. L. M. Specchio, L. Tramacere, A. La Neve, and E. Beghi, “Discontinuing Antiepileptic Drugs in Patients Who Are Seizure Free on Monotherapy,” Journal of Neurology, Neurosurgery, and Psychiatry 72, no. 1 (2002): 22–25, https://doi.org/10.1136/jnnp.72.1.22.

LinkOut - more resources